We feel now is a pretty good time to analyse Alkermes plc's (NASDAQ:ALKS) business as it appears the company may be on the cusp of a considerable accomplishment. Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. With the latest financial year loss of US$48m and a trailing-twelve-month loss of US$94m, the US$4.0b market-cap company amplified its loss by moving further away from its breakeven target. As path to profitability is the topic on Alkermes' investors mind, we've decided to gauge market sentiment. We've put together a brief outline of industry analyst expectations for the company, its year of breakeven and its implied growth rate.
See our latest analysis for Alkermes
Consensus from 10 of the American Biotechs analysts is that Alkermes is on the verge of breakeven. They anticipate the company to incur a final loss in 2023, before generating positive profits of US$57m in 2024. The company is therefore projected to breakeven around 2 years from now. In order to meet this breakeven date, we calculated the rate at which the company must grow year-on-year. It turns out an average annual growth rate of 77% is expected, which is extremely buoyant. If this rate turns out to be too aggressive, the company may become profitable much later than analysts predict.
NasdaqGS:ALKS Earnings Per Share Growth August 28th 2022
Underlying developments driving Alkermes' growth isn't the focus of this broad overview, though, keep in mind that typically biotechs, depending on the stage of product development, have irregular periods of cash flow. This means that a high growth rate is not unusual, especially if the company is currently in an investment period.
Before we wrap up, there's one aspect worth mentioning. The company has managed its capital judiciously, with debt making up 27% of equity. This means that it has predominantly funded its operations from equity capital, and its low debt obligation reduces the risk around investing in the loss-making company.
Next Steps:
There are too many aspects of Alkermes to cover in one brief article, but the key fundamentals for the company can all be found in one place – Alkermes' company page on Simply Wall St. We've also compiled a list of pertinent factors you should look at:
- Valuation: What is Alkermes worth today? Has the future growth potential already been factored into the price? The intrinsic value infographic in our free research report helps visualize whether Alkermes is currently mispriced by the market.
- Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on Alkermes's board and the CEO's background.
- Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
我们觉得现在是分析的好时机艾尔克姆斯公司(纳斯达克:ALKS)商业方面,该公司可能即将取得相当大的成就。Alkermes plc是一家生物制药公司,研究、开发和商业化药物产品,以满足美国、爱尔兰和国际上不同治疗领域患者未得到满足的医疗需求。这家市值40亿美元的公司最近一财年亏损4800万美元,往绩12个月亏损9400万美元,进一步远离盈亏平衡目标,扩大了亏损。由于盈利之路是Alkermes投资者关心的话题,我们决定衡量一下市场情绪。我们已经汇总了行业分析师对该公司的预期、盈亏平衡年和隐含增长率的简要概述。
查看我们对Alkermes的最新分析
10位美国生物技术分析师的共识是,Alkermes即将实现盈亏平衡。他们预计该公司将在2023年出现最终亏损,然后在2024年产生5700万美元的正利润。因此,该公司预计在大约两年后实现盈亏平衡。为了达到这个盈亏平衡日期,我们计算了公司必须同比增长的速度。事实证明,预计年均增长率为77%,这是非常令人振奋的。如果这一速度被证明过于激进,该公司实现盈利的时间可能比分析师预测的要晚得多。
纳斯达克:ALKS每股收益增长2022年8月28日
然而,推动Alkermes增长的潜在发展并不是本文的重点,但请记住,根据产品开发阶段的不同,生物技术公司通常会有不定期的现金流。这意味着高增长率并不罕见,尤其是如果公司目前处于投资期。
在我们结束之前,有一个方面值得一提。该公司对其资本进行了明智的管理,债务占股本的27%。这意味着它的运营资金主要来自股权资本,其较低的债务义务降低了投资这家亏损公司的风险。
接下来的步骤:
阿尔克梅斯涉及的方面太多了,一篇简短的文章无法涵盖,但该公司的关键基本面都可以在一个地方找到--阿尔克梅斯在Simply Wall St.上的公司页面。我们还整理了一系列相关因素,你应该看看:
- 估值:阿尔克梅斯今天值多少钱?未来的增长潜力已经计入价格因素了吗?我们免费研究报告中的内在价值信息图表有助于直观地了解Alkermes目前是否被市场错误定价。
- 管理团队:经验丰富的管理团队掌舵增加了我们对业务的信心-看看谁是Alkermes董事会的成员,以及CEO的背景。
- 其他高表现股票:有没有其他股票可以提供更好的前景,并有经过证实的记录?在这里探索我们的这些伟大股票的免费列表。
对这篇文章有什么反馈吗?担心内容吗? 保持联系直接与我们联系。或者,也可以给编辑组发电子邮件,地址是implywallst.com。
本文由Simply Wall St.撰写,具有概括性。我们仅使用不偏不倚的方法提供基于历史数据和分析师预测的评论,我们的文章并不打算作为财务建议。它不构成买卖任何股票的建议,也没有考虑你的目标或你的财务状况。我们的目标是为您带来由基本面数据驱动的长期重点分析。请注意,我们的分析可能不会将最新的对价格敏感的公司公告或定性材料考虑在内。Simply Wall St.对上述任何一只股票都没有持仓。